Saturday 17 October 2026 Export ACON’s income statement to Excel — free account

Aclarion, Inc.

ACON Healthcare Health Information Services

Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024. In the quarter to June 2026, revenue grew 30.6%, EPS grew 59.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.85 0.10 −5.13%

Follow ACON

Alert me

Market cap: $5.6M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 5/9
Altman Z: −4.92
Beneish M: −7.47
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	4	—	—	6	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 17.15%

Capital & Financial Ratios $m

Market Cap 5.63

Revenue 0.08

Net Income (9.20)

Free Cash Flow (8.26)

Net Debt (16.31)

Current Ratio 16.20

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.79)

P/S ratio 54.42

P/B ratio 0.27

Past 5Y EPS Growth —

This Y EPS Growth 65.27%

Next Y EPS Growth 35.44%

Next Y revenue growth 44.65%

Next 5Y EPS Growth 50.26%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 46.01%

10-year low 10-year high

P/B against its own 10 years 18.79%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	0	12	16
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	0	0	0
	1	1	12	17

	2023	2024	2025	Q'26
Payables	1	1	0	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	3	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	9.22%	7.82%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	79.32%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	—	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(1)	(2)	(7)
’24	(2)	(1)	(1)	(1)	(5)
’23	(1)	(1)	(1)	(1)	(4)
’22	0	(2)	(1)	(1)	(5)
’21	0	0	(1)	(1)	(2)
’20	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(1)	(2)	(7)
’24	(2)	(1)	(1)	(1)	(6)
’23	(1)	(1)	(1)	(1)	(4)
’22	0	(2)	(1)	(1)	(5)
’21	0	(1)	(1)	(1)	(3)
’20	—	—	—	(2)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.34)	(1.12)	—	—	—
’25	(9.32)	(2.75)	(2.93)	(2.01)	(13.61)
’24	(3.96k)	(1.35k)	(1.35k)	(757.02)	(7.48k)
’23	(21.62k)	(25.95k)	(17.30k)	(15.38k)	(79.46k)
’22	(1.03)	(0.45)	(0.21)	(166.88k)	(166.88k)
’21	(0.57)	(0.51)	(3.26)	(1.12)	(5.47)
’20	—	—	—	—	(0.69)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	54,993.60	26,194.32	904.50	4.32	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	586,116.00	342,986.41	61,053.75	3,500.42
People
People	Employees	—	—	—	—	—	6	7	6	6	11
	Revenue/emp, $m	—	—	—	0.00	0.00	0.01	0.01	0.01	0.01	0.01
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	0	0	0
	Gross margin, %	—	—	—	(576.58)	(36.14)	(14.76)	(8.11)	(0.40)	(85.12)	8.98
	EBT	—	—	—	(4)	(5)	(5)	(7)	(5)	(7)	(7)
	EBT margin, %	—	—	—	(14,941.64)	(9,517.86)	(8,209.45)	(11,702.98)	(6,513.79)	(15,301.75)	(9,555.61)
	Net income	—	0	—	(4)	(5)	(5)	(7)	(5)	(7)	(7)
	Depreciation	—	—	—	0	0	0	0	1	1	0
Per share, $
Per share, $	Revenue	—	—	—	0.06	0.01	0.07	0.00	754.00	50.78	0.14
	Earnings	—	—	—	(10.80)	(0.69)	(5.47)	(140,171.20)	(79,459.45)	(7,480.00)	(13.61)
	Cash flow	—	—	—	(9.29)	(0.27)	(2.65)	0.00	(36,469.00)	(5,857.33)	(13.47)
	Capex	—	—	—	0.00	(0.03)	(0.11)	0.00	(1,195.00)	(357.67)	(0.38)
	Free cash flow	—	—	—	(9.29)	(0.29)	(2.76)	0.00	(37,664.00)	(6,215.00)	(13.85)
	Book value	—	—	—	(3.79)	(1.05)	(6.33)	0.00	(7,280.00)	1,077.89	24.13
	Shares, m	—	—	—	0	7	1	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	6,200,318.40	6,200,318.40	6,200,318.40	0.00	39.68	25.65	32.33
	P/B	—	—	—	0.00	0.00	0.00	0.00	0.00	1.21	0.19
	EV/Sales	—	—	—	6,200,321.64	6,200,321.64	6,200,321.64	(20.46)	29.29	20.91	(123.47)
	EV/FCF	—	—	—	(138,507.57)	(138,507.57)	(138,507.57)	0.24	(0.59)	(0.17)	1.27
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(4)	(2)	(2)	(5)	(4)	(5)	(7)
	Capex	—	—	—	0	0	0	0	0	0	0
	Free cash flow	—	—	—	(4)	(2)	(3)	(5)	(4)	(6)	(7)
Balance, $m
Balance, $m	Working capital	—	—	—	(3)	(8)	(7)	1	(2)	0	12
	Total debt	—	—	—	1	0	2	0	—	—	—
	Net debt	—	—	—	0	0	0	(1)	(1)	0	(12)
	Shareholders’ equity	—	—	—	(2)	(7)	(6)	2	(1)	1	13
Returns, %
Returns, %	ROA	—	—	—	(677.67)	(403.12)	(374.43)	(311.57)	(182.77)	(307.75)	(91.67)
	ROIC	—	—	—	0.00	0.00	0.00	(467.71)	0.00	(680.42)	(554.92)
	ROE	—	—	—	0.00	124.90	59.81	141.13	(655.73)	(5,826.19)	(104.89)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RNLXY Renalytix plc - Sponsored ADR	$17.2M	— (loss-making)	—	+13.73% (above 0%: growing)	n/m	+17.96% (above 0%: growing)	19.16%	(783.91%)	Compare
BFRG Bullfrog AI Holdings Inc.	$9.9M	— (loss-making)	—	+2,054.00% (above 0%: growing)	n/m	−5.67% (below 0%: shrinking)	49.63%	(658.82%)	Compare
ETAOF ETAO International Co., Ltd.	$9.8M	— (loss-making)	—	—	n/m	+37,595.70% (above 0%: growing)	—	0.00%	Compare
HCTI Healthcare Triangle, Inc.	$7.4M	0.0×	— (loss-making)	+158.38% (above 0%: growing)	n/m	+67.48% (above 0%: growing)	22.48%	(44.28%)	Compare
MGRX Mangoceuticals, Inc.	$7.1M	— (loss-making)	—	−59.07% (below 0%: shrinking)	n/m	+79.27% (above 0%: growing)	64.24%	(1,501.45%)	Compare
HLTHQ Cue Health Inc.	$6.9M	— (loss-making)	— (loss-making)	−87.19% (below 0%: shrinking)	n/m	+50.55% (above 0%: growing)	(90.14%)	(792.13%)	Compare
ZCMD Zhongchao Inc.	$6.2M	— (loss-making)	—	+20.44% (above 0%: growing)	−550.00% (below 0%: shrinking)	+191.85% (above 0%: growing)	41.67%	0.00%	Compare
ACON Aclarion, Inc.	$5.6M	— (loss-making)	— (loss-making)	+30.57% (above 0%: growing)	n/m	−41.41% (below 0%: shrinking)	32.94%	(11,506.75%)
VSEED VSee Health, Inc.	$2.8M	— (loss-making)	— (loss-making)	+48.02% (above 0%: growing)	n/m	−257.62% (below 0%: shrinking)	13.20%	(172.69%)	Compare
Median of peers	$7.3M	—	—	+20.44%	—	+59.02%	22.48%	(415.75%)

All 51 Health Information Services stocks →

Aclarion, Inc. (ACON) key facts

Strength: Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024.
Aclarion, Inc. (ACON) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ACON traded at $1.85, a market capitalization of $5.6 million.
Return on equity was −104.9% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.92 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.